LoginSignup
Roche Holdings ADR logo

Roche Holdings ADR

Stock
Stock
ISIN: US7711951043
Ticker: RHHBY
US7711951043
RHHBY

Price

Price

Historical dividends and forecast

All dividend data

Roche Holdings ADR has so far distributed $1.307 in 2024. The next dividend will be paid on 03.05.2025

$1.103

CHART BY

Frequently asked questions

What is Roche Holdings ADR's market capitalization?

The market capitalization of Roche Holdings ADR is $230.60B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is Roche Holdings ADR's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for Roche Holdings ADR is 18.98. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for Roche Holdings ADR?

Roche Holdings ADR's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $14.90. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Roche Holdings ADR's stock?

Currently, 23 analysts cover Roche Holdings ADR's stock, with a consensus target price of $306.25. Analyst ratings provide insights into the stock's expected performance.

What is Roche Holdings ADR's revenue over the trailing twelve months?

Over the trailing twelve months, Roche Holdings ADR reported a revenue of $66.20B.

What is the EBITDA for Roche Holdings ADR?

Roche Holdings ADR's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $25.18B. EBITDA measures the company's overall financial performance.

What is the free cash flow of Roche Holdings ADR?

Roche Holdings ADR has a free cash flow of $3.74B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Roche Holdings ADR's stock?

The 5-year beta for Roche Holdings ADR is 0.73. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Roche Holdings ADR have, and what sector and industry does it belong to?

Roche Holdings ADR employs approximately 103,605 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Roche Holdings ADR's shares?

The free float of Roche Holdings ADR is 719.12M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $230.60B

5Y beta

 0.73

EPS (TTM)

 $14.90

Free Float

 719.12M

P/E ratio (TTM)

 18.98

Revenue (TTM)

 $66.20B

EBITDA (TTM)

 $25.18B

Free Cashflow (TTM)

 $3.74B

Pricing

1D span
$35.23$35.74
52W span
$29.03$42.83

Analyst Ratings

The price target is $306.25 and the stock is covered by 23 analysts.

Buy

9

Hold

8

Sell

6

Information

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

103,605

Biotechnology & Drugs

Health Care

Identifier

ISIN

US7711951043

Primary Ticker

RHHBY

Knockouts

Join the conversation
Sign upLogin